Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01465-4 In the MAINRITSEG clinical trial, treatment with rituximab did not confer an advantage over azathioprine for the maintenance of remission in patients with eosinophilic granulomatosis with polyangiitis.
Sarah Onuora. Rituximab not superior to azathioprine for EGPA remission maintenance. // Nature Reviews Rheumatology. – 2026. – DOI: 10.1038/s41584-026-01465-4. – URL: https://www.nature.com/articles/s41584-026-01465-4
Sarah Onuora (2026). Rituximab not superior to azathioprine for EGPA remission maintenance. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-026-01465-4
Sarah Onuora. “Rituximab not superior to azathioprine for EGPA remission maintenance.” Nature Reviews Rheumatology, 2026. doi:10.1038/s41584-026-01465-4.
@article{Onuora2026,
title = {Rituximab not superior to azathioprine for EGPA remission maintenance},
author = {Onuora, Sarah},
journal = {Nature Reviews Rheumatology},
year = {2026},
doi = {10.1038/s41584-026-01465-4},
url = {https://www.nature.com/articles/s41584-026-01465-4}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...